Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma

被引：26
|
作者：
Vose, J [1 ]
Sneller, V
机构：
[1] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA
[2] Baxter Oncol GmbH, Frankfurt, Germany
来源：
ANNALS OF ONCOLOGY | 2003年 / 14卷
关键词：
D O I：
10.1093/annonc/mdg704
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 20
页数：4
相关论文
共 50 条
  • [21] Dice (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory/relapsed non-Hodgkin's lymphoma (NHL).
    Coleman, M
    Leonard, JP
    Bayer, RL
    Gelfand, RM
    Kaufmann, TP
    BLOOD, 1999, 94 (10) : 523A - 523A
  • [22] Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin’s lymphoma
    Seon-Kyeong Kim
    Moo-Kon Song
    Joo Seop Chung
    Ho-Jin Shin
    International Journal of Hematology, 2013, 98 : 543 - 548
  • [23] DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)
    Coleman, M
    Leonard, J
    Shuster, MW
    Kaufman, TP
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 66 : 41 - 45
  • [24] Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma
    Kim, Seon-Kyeong
    Song, Moo-Kon
    Chung, Joo Seop
    Shin, Ho-Jin
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (05) : 543 - 548
  • [25] Rescue treatment with etoposide, platinum, ifosfamide and dexamethasone for non-Hodgkin's lymphoma
    Cervantes, G
    Torrecillas, L
    Erazo, A
    Jesus, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1204 - 1204
  • [26] Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy
    Abdayem, Pamela
    Ibrahim, Nathalie
    El Dakdouki, Yolla
    Willekens, Christophe
    Ghez, David
    Rouche, Julia A.
    Dartigues, Peggy
    Desmaris, Romain
    Danu, Alina
    Rossignol, Julien
    Lazarovici, Julien
    Ferme, Christophe
    Ribrag, Vincent
    Michot, Jean M.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (04) : 574 - 583
  • [27] High response rate but significant toxicity with sequential high-dose ifosfamide (I), carboplatin (C), and etoposide (E) with rituximab for relapsed Hodgkin's (HD) and large cell non-Hodgkin's lymphoma (NHL).
    Cocorocchio, E
    Antoniotti, P
    Calabrese, L
    Balzano, R
    Vanazzi, A
    Ferrucci, PF
    Raia, V
    Peccatori, F
    Martinelli, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 609S - 609S
  • [28] Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma
    Emmanouilides, C
    Lill, M
    Telatar, M
    Rosenfelt, F
    Grody, W
    Territo, M
    Rosen, P
    CLINICAL LYMPHOMA, 2002, 3 (02): : 111 - 116
  • [29] GEMCITABINE AND VINORELBINE (GV) VERSUS IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (ICE) REGIMEN IN TREATING PEDIATRIC PATIENTS WITH RECURRENT OR PROGRESSIVE HODGKIN'S LYMPHOMA
    Mahdy, Ahmed
    Hamoda, Asmaa
    Zaher, Ahmed
    Khorshed, Eman
    Elwakeel, Madeha
    Hassanein, Omneya
    Sidhom, Iman
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S204 - S204
  • [30] Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience
    Zinzani, PL
    ANNALS OF ONCOLOGY, 2003, 14 : 43 - 45
12345